SEC Form 4 · accession 0001209191-18-052550
AERIE PHARMACEUTICALS INC · AERI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard J Rubino
Officer — Chief Financial Officer
Period of report
Sep 26, 2018
Accepted (ET)
Sep 28, 2018 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001337553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Sep 26, 2018 | S | 49,500 | $60.1806 | D | 334,236 | D | |
| Common StockF2,F4 | Sep 26, 2018 | S | 500 | $61.01 | D | 333,736 | D | |
| Common StockF2,F5 | Sep 27, 2018 | S | 16,497 | $60.3623 | D | 317,239 | D | |
| Common StockF2,F6 | Sep 27, 2018 | S | 108 | $61.0111 | D | 317,131 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Following the sales reported on this Form 4, the reporting person's Rule 10b5-1 plan dated August 24, 2018 is completed.
- F2The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $60.00 to $60.95, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.00 to $61.05, inclusive.
- F5The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $60.00 to $60.90, inclusive.
- F6The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.00 to $61.15, inclusive.